Avicanna Inc., a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has entered into a sponsorship agreement with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”) to sponsor CICC in making available and providing access to the Canadian Cannabis Syllabus (“CCS”), continuing education course accredited by the University of Calgary’s Office of Continuing Medical Education and Professional Development, available to the Canadian medical community.
“We are proud to be sponsoring CCIC who have championed the advancement of evidence-based research and education on the endocannabinoid system in Canada. In line with the launch of MyMedi.ca and our commitment to advance medical cannabis access, we believe that the CCS can be an effective tool to provide education for healthcare providers and provide information to support the adoption of medical cannabis by the medical community,” stated Dr. Karolina Urban, EVP of Medical Affairs at Avicanna Inc.
“The CCIC is excited to develop this relationship with Avicanna as it will help to ensure the dissemination of accurate, scientifically valid and vetted information regarding the biology of cannabis and how it impacts the human body, potential therapeutic approaches that cannabis and cannabinoid products could be leveraged for with respect to specific disease states and putative health risks associated with cannabis use and the development of cannabis use disorder,” stated Dr. Matthew Hill, CCIC Executive Director.
Through the sponsorship agreement the CCS will be offered to healthcare providers interested in learning more about medical cannabis as a part of their practice. The CCS provides foundational knowledge and considerations for all healthcare professionals interested in learning more about cannabis and cannabinoid products in clinical practice. The course consists of 9 modules including:
- Introduction to the Endocannabinoid System
- Cannabis Basics
- Long-term Health Issues Associated with Cannabis
- Clinical Use of Cannabis and Cannabinoids in Pain (3 modules)
- Clinical Use of Cannabis in Non-pain Conditions
- Considerations when Authorizing Cannabis
- Acute Adverse Effects, Drug Interactions and Contraindications of Cannabis
- Cannabis Use Disorder
- Cannabis Policy in Canada
About the CCIC
The CCIC is a federally registered Canadian not-for-profit corporation of basic and clinical researchers, health care professionals and educators that promotes research and evidence-based education concerning the endocannabinoid system, the therapeutic applications of cannabinoids, the potential harms associated with cannabis use and the health and societal impacts of non-medical cannabis use. For more information, please visit https://ccic.net.
About Avicanna Inc.
Avicanna is a Canadian commercial-stage biopharmaceutical company focused on research, development, and commercialization of evidence-based cannabinoid products for medical and pharmaceutical market segments. Avicanna has an established scientific platform and intellectual property portfolio that has contributed to the international commercialization of over thirty products across various market segments.
Click to watch Avicanna’s Corporate Video 2022
For more information about Avicanna, visit our website, contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedIn, Twitter, Facebook, or Instagram. The Company posts updates through videos from the official Company YouTube channel.
